AXSM

129.2404.75%
ME

Mark E. Saad

Independent Director

Mr. Mark E. Saad serves as Partner and Chief Operating Officer of Alethea Capital Management, LLC. Mr. Saad is the CEO of NuLids, LLC, a portfolio company of Alethea Capital Management, LLC, an asset management firm based in Seattle for which he also serves as an advisor. Mr. Saad served as the Chief Financial Officer of Bird Rock Bio, Inc. since August 2014 to February 2017. He served as Consultant at Cytori Therapeutics, Inc, since August 11, 2014. Mr. Saad served as the Chief Financial Officer of Cytori Therapeutics, Inc, from June 23, 2004 to August 11, 2014. He served as Chief Operating Officer and Executive Director of UBS Investment Bank, Healthcare Investment Banking, New York, where he was responsible for global investment banking operations. He served as Chief Operating Officer of Global Healthcare Group. Upon joining UBS in 1999, Mr. Saad served as Director/Executive Director covering life sciences sectors - biotechnology and medical devices. Mr. Saad held a significant role in building the UBS franchise to become the largest healthcare group on Wall Street. Prior to joining UBS, Mr. Saad held the position of Financial Analyst/Associate with Salomon, Smith Barney, Healthcare Investment Banking, New York, where he managed public and private transactions. He served as a Director of Ra Medical Systems, Inc. since July 2018 until 2021. Mr. Saad serves on the board of directors of Presidium Health. Mr. Saad was part of the Health Care Investment Banking Group at Salomon Smith Barney, an investment bank. Mr. Saad served as Executive Director in the Investment Banking Department at UBS and also served as its calling officer. He worked with Salomon Smith Barney in its Healthcare Investment Banking Group from 1993 to 1999. Mr. Saad is a skilled financial and operations leader. He has been a Director at Axsome Therapeutics, Inc. since December 2014. Mr. Saad holds a BA in economics from Villanova University, Philadelphia, PA.

Positions